“…This may be due to the low positive predictive value of PSA, which accounts for a high proportion of unnecessary biopsies [4][5][6] . However, the negative predictive value (NPV) of TRUS-guided biopsy has been reported as between 36% and 89% [7] , with some patients being intolerant of this invasive procedure [8] . Where a negative biopsy is associated with continued suspicious clinical symptoms (continued rising PSA > 4.0 ng/mL, suspicious digital rectal examination, abnormal PSA velocity), repeat biopsies pose an even greater risk of negative rate for cancer detection than the initial biopsy (81%-83%) [9] , with second, third, and fourth re-biopsies detecting cancer in only 25% to 27%, 5% to 24%, and 4% to 21% of cases, respectively [10] .…”